Sarcoma Clinical Trial
Official title:
A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Background:
- Pazopanib, a drug that inhibits the growth of new blood vessels in tumors, was recently
approved by the Food and Drug Administration to treat advanced kidney cancer in adults.
Pazopanib has been used in only a small number of adults, and more research is needed on
whether it is safe and effective to use in children. Researchers are interested in
determining safe and effective treatment doses of pazopanib in children, and in other studies
will examine which form of pazopanib treatment (tablet or liquid) is most effective and well
tolerated.
Objectives:
- To determine a safe and effective dose of pazopanib to treat solid tumors in children.
- To study the effects of pazopanib on blood cells, blood flow, and human development.
Eligibility:
- Children, adolescents, and young adults between 1 and 21 years of age who have been
diagnosed with solid tumors that have not responded to treatment.
Design:
- Eligible participants will be screened with a physical examination, blood and tumor
samples, and imaging studies.
- Participants will receive pazopanib tablets for 28-day cycles of treatment. Pazopanib
should be taken on an empty stomach, at least 1hour before or 2 hours after a meal.
Participants may receive pazopanib for up to 24 cycles unless the tumor does not respond
or participants develop serious side effects.
- Blood samples will be taken on days 1, 15, 22, and 27 of the first cycle of pazopanib,
with additional samples taken every 8 weeks during subsequent cycles.
- An optional part of the study will collect additional blood samples at regular intervals
for 24 hours after the first dose of pazopanib and at regular intervals after another
dose during the second or third week of the first treatment cycle.
Background:
- Pazopanib is a potent and selective multi-target receptor tyrosine kinase inhibitor of
vascular endothelial growth factor (VEGF) receptors (VEGFR)-1, -2, and -3, c-kit and
platelet derived growth factor (PDGF) receptors-alpha and -beta.
- Preclinical experiments demonstrate that pazopanib causes significant and dose-dependent
inhibitory effects on cell proliferation and inhibition of VEGF-induced VEGFR-2
phosphorylation, growth inhibition of a variety of human tumor xenografts in mice, and
inhibition of basic fibroblast growth factor-(bFGF) and VEGF-induced angiogenesis in
murine models.
- Pazopanib has been evaluated in adult subjects with solid tumors in Phase I and II
studies, and objective anti-tumor activity has been observed in a variety of tumor
types.
Objectives:
Primary Objectives:
- To estimate maximum tolerated dose (MTD) and/or recommended Phase II dose of oral
pazopanib administered on a once daily schedule to children with refractory solid
tumors.
- To define the toxicities of oral pazopanib administered as either a tablet or
suspension.
- To characterize the pharmacokinetics of oral pazopanib in children with refractory solid
tumors.
Secondary Objectives:
- To preliminarily define the antitumor and biologic activity of oral pazopanib, and to
explore the changes in tumor vascular permeability following initiation of pazopanib.
- To preliminarily assess VEGF haplotype/phenotype relationships in children with cancer.
- To explore pazopanib concentration-effect relationships with biomarkers and with
clinical outcomes.
Eligibility:
- Part 1 (Phase I Dose Escalation) and 2a (Suspension Formulation Component):
--Patients greater than 12 months and less than or equal to 21 years of age with
measureable or evaluable relapsed or refractory solid tumors including CNS tumors with
histologic verification except in patients with intrinsic brain stem tumors, optic
pathway gliomas, or patients with pineal tumors and elevation of tumor markers.
- Part 2b (Expanded Imaging Cohort):
--Patients greater than 2 years and less than or equal to 25 years of age with
histologically verified relapsed or refractory soft tissue sarcoma, desmoplastic small
round cell tumor or extraosseus Ewing sarcoma with measurable disease (greater than or
equal to 2 cm) in the head, neck, extremity or fixed within the thorax, abdomen or
pelvis.
- Performance score: Karnofsky greater than or equal to 50% for patients 16 years of age;
Lansky greater than or equal to 50 for patients less than or equal to 16 years of age.
- Must have fully recovered from acute toxic effects from all prior therapy which have
been completed within the specified prior time frame. Have adequate organ function as
determined by laboratory evaluation.
Design:
- This is a rolling six phase I trial design of pazopanib administered orally once daily
continuously on a 28 day cycle.
- Therapy may continue for up to 24 cycles in the absence of progressive disease or
unacceptable toxicity.
- Part 1 is the phase I dose escalation portion (Completed). Once the MTD or phase II
recommended dose is defined, up to 16 additional patients will enroll in Part 2a to
obtain safety and pharmacokinetic data for the suspension formulation. In addition, up
to 10 patients with recurrent/refractory soft tissue sarcoma and a measurable lesion
will be enrolled in Part 2b at the MTD or recommended Phase II dose to further explore
changes in tumor vascular permeability using dynamic contrast enhanced MRI.
- Participation in correlative biology studies or pharmacokinetic studies will be optional
in Part 1; pharmacokinetic studies will be required in Part 2a; and imaging and limited
pharmacokinetic sampling will be required in Part 2b.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |